BR112014016764A2 - métodos de bloqueio de ativação de plaqueta durante circulação extracorpórea usando cangrelor - Google Patents

métodos de bloqueio de ativação de plaqueta durante circulação extracorpórea usando cangrelor

Info

Publication number
BR112014016764A2
BR112014016764A2 BR112014016764A BR112014016764A BR112014016764A2 BR 112014016764 A2 BR112014016764 A2 BR 112014016764A2 BR 112014016764 A BR112014016764 A BR 112014016764A BR 112014016764 A BR112014016764 A BR 112014016764A BR 112014016764 A2 BR112014016764 A2 BR 112014016764A2
Authority
BR
Brazil
Prior art keywords
platelet
methods
cangrelor
hypothermia
inhibition
Prior art date
Application number
BR112014016764A
Other languages
English (en)
Other versions
BR112014016764A8 (pt
Inventor
Straub Andreas
Stolz Angelika
Neumann Bernd
Balkau Beverley
Peter Wendel Hans
Kurz Julia
Peter Karlheinz
Unertl Klaus
Krajewski Stefanie
O Greiner Tim
Original Assignee
The Medicines Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Medicines Co filed Critical The Medicines Co
Publication of BR112014016764A2 publication Critical patent/BR112014016764A2/pt
Publication of BR112014016764A8 publication Critical patent/BR112014016764A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

abstract the present invention is directed to methods of protecting platelets during medical procedures that include extracorporeal circulation (ecc) or hypothermia, or both. the methods comprise administering a pharmaceutical composition comprising the p2y12 adp receptor blocker cangrelor to a subject undergoing a medical procedure that includes ecc or hypothermia, or both. the protection of platelets through the methods of the present invention includes inhibiting activation of platelets, inhibiting platelet granule release, inhibiting platelet- leukocyte aggregation and inhibiting platelet loss from the blood of the subject. ************************** tradução do resumo resumo patente de invenção: "métodos de bloqueio de ativação de plaqueta durante circulação extracorpórea usando cangrelor". a presente invenção refere-se a métodos de proteção de plaquetas durante procedimentos médicos que incluem circulação extracorpórea (ecc) ou hipotermia ou ambas. os métodos compreendem administrar uma composição farmacêutica compreendendo o bloqueador de receptor de adp p2y12 cangrelor a um indivíduo sofrendo um procedimento médico que inclui ecc ou hipotermia ou ambos. a proteção de plaquetas através dos métodos da presente invencao inclui inibição de ativação de plaquetas, inibição de liberação de grânulo plaquetário, inibição de agregação de plaqueta-leucócito e inibição de perda de plaqueta a partir do sangue do indivíduo. 21738814v1 1/1 21738814v1
BR112014016764A 2012-01-04 2012-12-26 métodos de bloqueio de ativação de plaqueta durante circulação extracorpórea usando cangrelor BR112014016764A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261582994P 2012-01-04 2012-01-04
PCT/US2012/071666 WO2013103567A2 (en) 2012-01-04 2012-12-26 Methods of blocking platelet activation during extracorporeal circulation using cangrelor

Publications (2)

Publication Number Publication Date
BR112014016764A2 true BR112014016764A2 (pt) 2017-06-13
BR112014016764A8 BR112014016764A8 (pt) 2017-07-04

Family

ID=48745531

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014016764A BR112014016764A8 (pt) 2012-01-04 2012-12-26 métodos de bloqueio de ativação de plaqueta durante circulação extracorpórea usando cangrelor

Country Status (2)

Country Link
BR (1) BR112014016764A8 (pt)
WO (1) WO2013103567A2 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2971868C (en) * 2015-01-14 2023-04-04 Chiesi Farmaceutici S.P.A. Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same

Also Published As

Publication number Publication date
WO2013103567A2 (en) 2013-07-11
BR112014016764A8 (pt) 2017-07-04

Similar Documents

Publication Publication Date Title
BR112015012197A8 (pt) usos de inibidores de cdk mtor, e combinação farmacêutica compreendendo os mesmos
BR112015009503A2 (pt) dispostivo de tratamento extracorporal do sangue
EA202090955A1 (ru) Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
BR112015020804A2 (pt) dispositivo fototerapeutico, método e uso
BR112018015289A2 (pt) compostos de benzopirazol e análogos dos mesmos
BR112015026006A8 (pt) composto em combinação com um fármaco imunomodulador imid®, composição farmacêutica que os compreende, uso dos mesmos e kit
BR112014032699A2 (pt) métodos de tratamento de síndrome metabólica pediátrica
BR112015001419A2 (pt) composto, composição farmacêutica, e, métodos para inibir romk em um paciente, para causar diurese, natriurese ou ambos e para tratamento de um ou mais distúrbios
BR112015024711A2 (pt) cartucho de fluido para dispositivo médico de infusão
BR112018014027A2 (pt) composições e métodos para administração intravenosa de 2-bromo-1-(3,3-dinitroazeditin-1-il)etanona
BR112015009948A8 (pt) Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios
HRP20200009T1 (hr) Angiotenzin ii u kombinaciji za liječenje hipotenzije
BR112014016810A2 (pt) composições e métodos para tratamento de distúrbios metabólicos
BR112018016341A2 (pt) solução de bloqueio do cateter e terapia de bloqueio do cateter
BR112015019039A8 (pt) compostos antagonistas de integrina fluorados, composição farmacêutica compreendendo ditos compostos e uso destes para tratar ou prevenir uma doença ou condição mediada por uma av integrina
MY175997A (en) Antl-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig protein scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
BR112015022650A2 (pt) inibidores de cinase induzível por sal macrocíclico
BR112015011778A2 (pt) métodos para administrar e avaliar drogas de expulsão de nitrogênio para o tratamento de encefalopatia hepática
BR112012022552A8 (pt) uso de fenoterol e de análogos de fenoterol no tratamento de gliobastomas e astrocitomas e composição farmacêutica compreendendo os referidos compostos
BR112012027092A2 (pt) métodos e composiões para reduzir ou impedir a calcificação vascular durante a terapia de diálise peritoneal
BR112017006272A2 (pt) composição farmacêutica para tratar colite ulcerativa.
BR112012016783A2 (pt) "usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia"
BR112013027486A2 (pt) combinação de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor
BR112014016764A2 (pt) métodos de bloqueio de ativação de plaqueta durante circulação extracorpórea usando cangrelor
BR112013001462B8 (pt) Composições

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired
B350 Update of information on the portal [chapter 15.35 patent gazette]